Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Alnylam Pharmaceuticals (ALNY) is actively diversifying its revenue streams beyond its primary drug, Amvuttra, through the expanded global adoption of therapies like Givlaari and Oxlumo, which generated $236.8 million in net product revenues in H1 2025, a 16% year-over-year increase, alongside royalties from Novartis's Leqvio. This strategy is critical as Amvuttra faces intensifying competition in the ATTR-CM market from rivals such as Pfizer's Vyndaqel/Vyndamax, which reported $3.1 billion in H1 2025 revenues, and BridgeBio's recently launched Attruby, which generated $108.2 million in the same period. Alnylam's broader portfolio and global expansion efforts are essential to sustain top-line growth and reduce reliance on its lead drug amidst this competitive landscape.

Analysis

Alnylam Pharmaceuticals (ALNY) is actively executing a revenue diversification strategy to mitigate its reliance on the primary top-line driver, Amvuttra. This is supported by its rare disease portfolio, comprising Givlaari and Oxlumo, which generated $236.8 million in the first half of 2025, reflecting a 16% year-over-year increase. The strategy's urgency is underscored by the intensifying competition for Amvuttra in the lucrative ATTR-CM market. Key rivals include Pfizer's (PFE) established Vyndaqel family, which posted significant revenues of $3.1 billion in H1 2025 (a 27% YoY increase), and BridgeBio's (BBIO) new entrant, Attruby, which has shown rapid uptake with $108.2 million in sales in H1 2025 since its late 2024 launch. While the positive sentiment for ALNY (0.6) indicates market confidence in its growth initiatives, the overall cautious tone of the situation highlights that the company's future performance hinges on its ability to expand the global reach and indications of its broader portfolio to offset the significant and growing competitive pressure on its lead drug.

Key Decisions for Investors

• Investors should closely monitor the revenue growth and global adoption rates of Alnylam's secondary products, Givlaari and Oxlumo, as their performance is critical to validating the company's diversification strategy away from Amvuttra.
• It is crucial to track the prescription trends and quarterly sales figures for competitive therapies, specifically BridgeBio's Attruby and Pfizer's Vyndaqel, as these are direct indicators of market share dynamics in the ATTR-CM space.
• Consider the success of Alnylam's pending regulatory filings and late-stage studies for label expansions as key catalysts, as these outcomes will determine the company's ability to sustain top-line growth against well-funded competitors.